In six acromegalic patients resistant to somatostatin analogs, serum total IGF-1 normalized with pegvisomant.
In plain wordsIn acromegaly resistant to somatostatin analogs, IGF-1 normalized with pegvisomant.
- Peptide
- Pegvisomant
- Outcome
- DecreaseIGF-1 normalization
- Study
n = 6
- Comparator
- Baseline
- Outcome group
- Growth hormone and IGF-1 · Endocrine and hormones
- Studied dose
- Dose not stated
Measurements
- Patients with normalized serum total IGF-1
- 6 patients
- all six octreotide-resistant patients
Source sentences
Serum total IGF-1 levels were normalized in all six acromegalic patients previously shown to be resistant to somatostatin analogs via a novel mechanism of peripheral GH receptor antagonism.
2 context sentences(design, population, supporting numbers)
Six patients resistant to maximal doses of octreotide therapy received pegvisomant - three received placebo or pegvisomant 30 mg or 80 mg weekly for 6 weeks and three received placebo and pegvisomant 10-20 mg/d for 12 weeks.
Thereafter, all patients received daily pegvisomant injections of doses determined by titrating IGF-1 levels.